| Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer J Cortés, SB Kim, WP Chung, SA Im, YH Park, R Hegg, MH Kim, ... New England Journal of Medicine 386 (12), 1143-1154, 2022 | 660 | 2022 |
| Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma HD Kim, GW Song, S Park, MK Jung, MH Kim, HJ Kang, C Yoo, K Yi, ... Gastroenterology 155 (6), 1936-1950. e17, 2018 | 246 | 2018 |
| Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation MH Kim, J Kim, H Hong, SH Lee, JK Lee, E Jung, J Kim The EMBO journal 35 (5), 462-478, 2016 | 244 | 2016 |
| Actin remodelling factors control ciliogenesis by regulating YAP/TAZ activity and vesicle trafficking J Kim, H Jo, H Hong, MH Kim, JM Kim, JK Lee, WD Heo, J Kim Nature communications 6 (1), 6781, 2015 | 193 | 2015 |
| YAP-induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma MH Kim, CG Kim, SK Kim, SJ Shin, EA Choe, SH Park, EC Shin, J Kim Cancer immunology research 6 (3), 255-266, 2018 | 177 | 2018 |
| Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies MH Kim, J Kim Cellular and Molecular Life Sciences 74, 1457-1474, 2017 | 88 | 2017 |
| Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma MH Kim, HS Shim, DR Kang, JY Jung, CY Lee, DJ Kim, JG Lee, MK Bae, ... Lung cancer 83 (3), 389-395, 2014 | 70 | 2014 |
| Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations MH Kim, HR Kim, BC Cho, MK Bae, EY Kim, CY Lee, JS Lee, DR Kang, ... Lung cancer 84 (2), 196-202, 2014 | 68 | 2014 |
| Molecular characterization of biliary tract cancer predicts chemotherapy and programmed death 1/programmed death‐ligand 1 blockade responses JG Yoon, MH Kim, MI Jang, H Kim, HK Hwang, CM Kang, WJ Lee, B Kang, ... Hepatology 74 (4), 1914-1931, 2021 | 48 | 2021 |
| MK5 regulates YAP stability and is a molecular target in YAP-driven cancers J Seo, MH Kim, H Hong, H Cho, S Park, SK Kim, J Kim Cancer research 79 (24), 6139-6152, 2019 | 34 | 2019 |
| FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients MH Kim, JS Koo, S Lee Oncology 85 (2), 128-136, 2013 | 25 | 2013 |
| Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response MH Kim, JH Kim, JM Lee, JW Choi, D Jung, H Cho, H Kang, MH Hong, ... British journal of cancer 122 (11), 1649-1660, 2020 | 23 | 2020 |
| Ifosfamide-induced Fanconi syndrome with diabetes insipidus AY Leem, HS Kim, BW Yoo, BD Kang, MH Kim, SY Rha, HS Kim The Korean Journal of Internal Medicine 29 (2), 246, 2014 | 21 | 2014 |
| Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication MH Kim, S Lee, JS Koo, KH Jung, IH Park, J Jeong, SI Kim, S Park, ... PloS one 10 (3), e0120320, 2015 | 15 | 2015 |
| Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older MH Kim, GM Kim, JH Kim, JY Kim, HS Park, S Park, YU Cho, BW Park, ... Breast Cancer Research and Treatment 179, 687-697, 2020 | 14 | 2020 |
| Immunohistochemistry biomarkers predict survival in stage II/III gastric cancer patients: from a prospective clinical trial MH Kim, X Zhang, M Jung, I Jung, HS Park, SH Beom, HS Kim, SY Rha, ... Cancer research and treatment: official journal of Korean Cancer Association …, 2019 | 14 | 2019 |
| Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater MH Kim, M Jang, H Kim, WJ Lee, CM Kang, HJ Choi Cancer Immunology, Immunotherapy 68, 443-454, 2019 | 9 | 2019 |
| SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models CB Synn, SE Kim, HK Lee, MH Kim, JH Kim, JM Lee, HN Jo, W Lee, ... Clinical & Translational Immunology 11 (1), e1364, 2022 | 8 | 2022 |
| Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial M Takahashi, J Cortés, R Dent, L Pusztai, H McArthur, S Kümmel, ... JAMA network open 6 (11), e2342107-e2342107, 2023 | 5 | 2023 |
| Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study Y Drew, JW Kim, RT Penson, DM O'Malley, C Parkinson, P Roxburgh, ... Clinical Cancer Research 30 (1), 50-62, 2024 | 4 | 2024 |
Joon KimKAISTVerified email at kaist.ac.kr
Joon KimKAISTVerified email at kaist.ac.kr